KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.95

Calmangafodipir for Prevention of Oxaliplatin-Induced Peripheral Neuropathy: Two Placebo-Controlled, Randomized Phase 3 Studies (POLAR-A/POLAR-M).

Per Pfeiffer, Maryam Lustberg, Jacques Näsström, Stefan Carlsson, Anders Persson, Fumiko Nagahama, Guido Cavaletti, Bengt Glimelius, Kei Muro

JNCI Cancer Spectr 6(6) pkac075

PMID36308441
PMCIDPMC9678401
DOI10.1093/jncics/pkac075
发表日期2022-10-29
入排依据:The study is a randomized, placebo-controlled Phase 3 oncology trial with a drug intervention and reports original primary results. However, the primary endpoint is a binary patient-reported outcome (incidence of moderate-to-severe CIPN at a fixed time point), not a time-to-event efficacy endpoint (such as OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier estimation or hazard ratio. Therefore, it does not meet the time-to-event criterion for inclusion.
摘要

摘要

BACKGROUND: Calmangafodipir (CaM, PledOx) demonstrated efficacy in preventing patient-reported chemotherapy-induced peripheral neuropathy (CIPN) in a randomized phase 2 study in patients with metastatic colorectal cancer. The Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy (POLAR) program aimed to assess efficacy and safety of CaM in the prevention of CIPN in patients treated with oxaliplatin in adjuvant (POLAR-A, ClinicalTrials.gov.NCT04034355) or metastatic (POLAR-M, ClinicalTrials.gov.NCT03654729) settings. METHODS: Two randomized, placebo-controlled phase 3 trials investigated patient-reported, moderate-to-severe CIPN 9 months after beginning folinic acid, 5-fluorouracil, and oxaliplatin therapy with or without CaM. In POLAR-A, patients with stage III or high-risk stage II colorectal cancer were randomly assigned 1:1 to receive CaM 5 μmol/kg or placebo. In POLAR-M, patients with metastatic colorectal cancer were randomly assigned 1:1:1 to receive CaM 5 μmol/kg, CaM 2 μmol/kg, or placebo. RESULTS: POLAR-A (n = 301) and POLAR-M (n = 291) were terminated early following unexpected hypersensitivity reactions in CaM-treated patients. In a combined analysis of month 9 CIPN (primary endpoint) data from both trials (CaM 5 μmol/kg, n = 175; placebo, n = 176), 54.3% of patients in the CaM group had moderate-to-severe CIPN compared with 40.3% in the placebo group. The estimated relative risk for moderate-to-severe CIPN at month 9 was 1.37 (95% confidence interval = 1.01 to 1.86; P = .045). A higher proportion of patients experienced serious hypersensitivity reactions across both trials with CaM treatment (3.6%) than with placebo (0.8%). CONCLUSION: The POLAR clinical studies failed to meet their primary endpoint. These results highlight the challenges of targeting oxidative stress for preventing CIPN in both the adjuvant and metastatic settings.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。